Liqian Mo

488 total citations
22 papers, 414 citations indexed

About

Liqian Mo is a scholar working on Pharmacology, Molecular Biology and Nephrology. According to data from OpenAlex, Liqian Mo has authored 22 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Molecular Biology and 4 papers in Nephrology. Recurrent topics in Liqian Mo's work include Pharmacological Effects and Toxicity Studies (4 papers), Advanced Glycation End Products research (4 papers) and Chronic Kidney Disease and Diabetes (3 papers). Liqian Mo is often cited by papers focused on Pharmacological Effects and Toxicity Studies (4 papers), Advanced Glycation End Products research (4 papers) and Chronic Kidney Disease and Diabetes (3 papers). Liqian Mo collaborates with scholars based in China. Liqian Mo's co-authors include Xiaoyan Xiao, Qifu Wang, Zhiyuan Zhu, Chun‐Nan Lin, Huiqing Wang, Yongyi Ye, Haoyuan Wang, Xin Gong, Xiaozheng He and Guohui Lu and has published in prestigious journals such as Biochemical and Biophysical Research Communications, International Journal of Pharmaceutics and Toxicology and Applied Pharmacology.

In The Last Decade

Liqian Mo

20 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liqian Mo China 10 230 115 65 40 37 22 414
Lina Zhou China 17 261 1.1× 68 0.6× 38 0.6× 52 1.3× 50 1.4× 49 596
Xianghong Lu China 13 304 1.3× 49 0.4× 69 1.1× 24 0.6× 33 0.9× 20 577
Gan Qiao China 15 436 1.9× 166 1.4× 99 1.5× 41 1.0× 21 0.6× 37 754
Hassan Akrami Iran 14 267 1.2× 120 1.0× 24 0.4× 16 0.4× 32 0.9× 53 536
Lili Chi China 12 185 0.8× 48 0.4× 29 0.4× 18 0.5× 27 0.7× 29 447
Tingzhun Zhu China 14 232 1.0× 57 0.5× 77 1.2× 21 0.5× 20 0.5× 21 435
Yu‐Chang Liu Taiwan 20 421 1.8× 160 1.4× 34 0.5× 22 0.6× 53 1.4× 34 748
Anqi Xu China 13 257 1.1× 103 0.9× 88 1.4× 22 0.6× 16 0.4× 47 548
Anheng Liu China 10 279 1.2× 58 0.5× 31 0.5× 35 0.9× 15 0.4× 14 434
Cuixiang Zhang China 9 243 1.1× 77 0.7× 38 0.6× 10 0.3× 17 0.5× 13 494

Countries citing papers authored by Liqian Mo

Since Specialization
Citations

This map shows the geographic impact of Liqian Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqian Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqian Mo more than expected).

Fields of papers citing papers by Liqian Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liqian Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqian Mo. The network helps show where Liqian Mo may publish in the future.

Co-authorship network of co-authors of Liqian Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Liqian Mo. A scholar is included among the top collaborators of Liqian Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqian Mo. Liqian Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hui, Jialiang, et al.. (2025). Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice. Clinical Immunology. 273. 110445–110445. 1 indexed citations
2.
3.
Mo, Liqian, et al.. (2023). Pharmaceutical care model in precision medicine in China. Farmacia Hospitalaria. 47(5). 218–223. 1 indexed citations
4.
Mo, Liqian, et al.. (2023). [Artículo traducido] Modelo de atención farmacéutica en medicina de precisión en China. Farmacia Hospitalaria. 47(5). T218–T223.
5.
6.
Xun, Tianrong, et al.. (2022). Advanced oxidation protein products upregulate ABCB1 expression and activity via HDAC2-Foxo3α-mediated signaling in vitro and in vivo. Toxicology and Applied Pharmacology. 449. 116140–116140. 4 indexed citations
7.
Yu, Ze, Liqian Mo, Yuqing Zhang, et al.. (2022). An individualized medication model of sodium valproate for patients with bipolar disorder based on machine learning and deep learning techniques. Frontiers in Pharmacology. 13. 890221–890221. 8 indexed citations
8.
9.
Wang, Xiaokang, Chunxiao Ye, Tianrong Xun, et al.. (2021). Bacteroides Fragilis Polysaccharide A Ameliorates Abnormal Voriconazole Metabolism Accompanied With the Inhibition of TLR4/NF-κB Pathway. Frontiers in Pharmacology. 12. 663325–663325. 23 indexed citations
10.
Xun, Tianrong, et al.. (2020). Advanced oxidation protein products upregulate efflux transporter expression and activity through activation of the Nrf-2-mediated signaling pathway in vitro and in vivo. European Journal of Pharmaceutical Sciences. 149. 105342–105342. 10 indexed citations
11.
Hu, Hongling, et al.. (2020). AGE receptor 1 silencing enhances advanced oxidative protein product-induced epithelial-to-mesenchymal transition of human kidney proximal tubular epithelial cells via RAGE activation. Biochemical and Biophysical Research Communications. 529(4). 1201–1208. 9 indexed citations
12.
Mo, Liqian & Ping Zheng. (2020). [Chloroquine phosphate: therapeutic drug for COVID-19].. PubMed. 40(4). 586–594. 4 indexed citations
13.
Xiao, Xiaoyan, et al.. (2017). Protective effects of Paeoniflorin against AOPP-induced oxidative injury in HUVECs by blocking the ROS-HIF-1α/VEGF pathway. Phytomedicine. 34. 115–126. 57 indexed citations
14.
Mo, Liqian, et al.. (2017). Huang Gan Formula Eliminates the Oxidative Stress Effects of Advanced Oxidation Protein Products on the Divergent Regulation of the Expression of AGEs Receptors via the JAK2/STAT3 Pathway. Evidence-based Complementary and Alternative Medicine. 2017(1). 4520916–4520916. 5 indexed citations
15.
16.
Mo, Liqian, et al.. (2015). Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway. Drug Design Development and Therapy. 9. 2867–2867. 17 indexed citations
17.
Li, Xiao, Lianbing Hou, Li Yang, et al.. (2014). Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma. International Journal of Nanomedicine. 9. 3971–3971. 27 indexed citations
18.
Xiao, Wei, et al.. (2014). Paeonol Attenuates Advanced Oxidation Protein Product-Induced Oxidative Stress Injury in THP-1 Macrophages. Pharmacology. 93(5-6). 286–295. 14 indexed citations
19.
Xiao, Xiaoyan, et al.. (2014). [Compound Huang Gan delays chronic renal failure after 5/6 nephrectomy in rats].. PubMed. 34(11). 1661–7. 1 indexed citations
20.
Mo, Liqian, et al.. (2012). Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. International Journal of Pharmaceutics. 436(1-2). 815–824. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lina Zhou Breakdown of academic impact, for papers by Xianghong Lu Breakdown of academic impact, for papers by Gan Qiao Breakdown of academic impact, for papers by Hassan Akrami Breakdown of academic impact, for papers by Lili Chi Breakdown of academic impact, for papers by Tingzhun Zhu Breakdown of academic impact, for papers by Yu‐Chang Liu Breakdown of academic impact, for papers by Anqi Xu Breakdown of academic impact, for papers by Anheng Liu Breakdown of academic impact, for papers by Cuixiang Zhang
Rankless by CCL
2026